Home › Trials › NCT06605885

Evaluating asthma biologic use and outcomes in Chinese patients

An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients

Observational AstraZeneca · NCT06605885

This study is testing how well asthma medications called biologics work for patients in China and how they affect their health and quality of life over a year.

Quick facts

Study typeObservational
Enrollment200 (estimated)
SexAll
SponsorAstraZeneca Industry-sponsored
Locations32 sites (Beijing and 31 other locations)
Trial IDNCT06605885 on ClinicalTrials.gov

What this trial studies

This observational study aims to assess the use of biologics in asthma treatment and the resulting clinical outcomes among patients in China. Approximately 200 patients diagnosed with asthma and prescribed biologics will be enrolled across 50 sites. Participants will undergo clinical assessments and standard medical care, with follow-ups at 24 and 52 weeks to collect data on their health status and quality of life. The study will utilize existing medical records and patient-reported outcomes to evaluate the effectiveness of biologics in managing asthma.

Who should consider this trial

Good fit: Ideal candidates include Chinese individuals of any age with a physician-confirmed diagnosis of asthma who have been prescribed biologics.

Not a fit: Patients who have participated in an interventional study within the last 3 months or have significant comorbidities may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the effectiveness of biologics for asthma treatment in the Chinese population.

How similar studies have performed: While there have been studies on asthma biologics, this specific observational approach in the Chinese population is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Chinese, Female or Male
2. Age: no limitation
3. Physician-confirmed asthma diagnosis with documented evidence of diagnosis or evidence of variable expiratory airflow limitation (e.g., from bronchodilator reversibility testing or other tests).
4. Participants or their legal guardians must be able to provide informed consent.
5. Prescription of asthma biologics at enrolment.

   Exclusion Criteria:
6. Participation in an interventional study within the last 3 months.
7. Any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study with the usage of biologics, or may influence the results of the study, or the patient's ability to participate in the study

Where this trial is running

Beijing and 31 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Asthma
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.